A good showing by Parsortix
SURREY, U.K.—ANGLE plc's clinical study of Parsortix in metastatic breast cancer delivered positive results, the company announced recently. The study was meant to support a de-novo submission to the FDA for Class II regulatory clearance for the Parsortix system, and successfully demonstrated the system's ability to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients. In addition, the harvested cells were able to be interrogated via several analysis techniques and were viable for use in generating cDNA libraries of sufficient quality for RNA-seq evaluation. ANGLE noted that additional experiments will be necessary to support the clearance, but the company still expects that it will be able to complete all studies and submit early in the fourth quarter of this year to enable FDA clearance in early 2020.